机构：[1]Department of Obstetrics, West China Women’s and Children’s Hospital,[2]Key Laboratory of Birth and Related Diseases of Women and Children, Sichuan University,[3]Center for Joint Surgery, Southwest Hospital, Third Military Medical University,[4]Department of Cosmetic Plastic and Burns Surgery, West China Hospital,四川大学华西医院[5]National Drug Clinical Trial Institute, West China Second University Hospital, Sichuan University,[6]Department of West China Second University Hospital Quality Improvement, West China Women’s and Children’s Hospital, Chengdu,[7]Karamay Central Hospital, XinJiang, PR China.
Accumulating evidence has demonstrated that leptin is associated to the tumorigenesis and progression of breast cancer (BC). However, these studies remain inconsistent. Thus, a meta-analysis was conducted to investigate the role of leptin in the patients with BC.
A systematic search in PubMed, Embase, ISI Web of Science, and Chinese National Knowledge Infrastructure (CNKI) databases was conducted up to September 1, 2017. The standardized mean difference (SMD) with 95% confidence interval (CI) was applied to pool the effect size. A funnel plot and Egger test were used to evaluate publication bias.
Finally, 43 eligible studies were included in the current meta-analysis. Overall, serum leptin levels in BC cases were significantly higher compared with the controls (SMD = 0.61, P <.0001). When subgroup analyses were restricted to ethnicity and menstrual status, higher serum leptin concentration was also detected in patients with BC. Moreover, BC cases with body mass index (BMI) >25 indicated significantly higher serum leptin levels (SMD = 1.48, P = .034). Furthermore, the BC cases with lymph node metastases showed significantly higher serum leptin concentration (SMD = 0.53, P = .015).
The present meta-analysis suggests that the serum leptin may profiles as a pivotal role in the pathogenesis and metastasis of BC. In addition, leptin will provide useful information for a therapeutic target to treat BC.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|4 区医学
小类|3 区医学：内科
最新[2023]版：
大类|4 区医学
小类|4 区医学：内科
第一作者：
第一作者机构：[1]Department of Obstetrics, West China Women’s and Children’s Hospital,[2]Key Laboratory of Birth and Related Diseases of Women and Children, Sichuan University,
共同第一作者：
通讯作者：
通讯机构：[2]Key Laboratory of Birth and Related Diseases of Women and Children, Sichuan University,[6]Department of West China Second University Hospital Quality Improvement, West China Women’s and Children’s Hospital, Chengdu,[*1]Key Laboratory of Birth and Related Diseases of Women and Children, Sichuan University, Chengdu, PR China, Department of West China Second University Hospital Quality Improvement, West China Women’s and Children’s Hospital, Chengdu, PR China
推荐引用方式(GB/T 7714)：
Gu Li,Wang Cheng-Di,Cao Chang,et al.Association of serum leptin with breast cancer: A meta-analysis.[J].Medicine.2019,98(5):e14094.doi:10.1097/MD.0000000000014094.
APA：
Gu Li,Wang Cheng-Di,Cao Chang,Cai Lin-Rui,Li De-Hua&Zheng Yu-Zhen.(2019).Association of serum leptin with breast cancer: A meta-analysis..Medicine,98,(5)
MLA：
Gu Li,et al."Association of serum leptin with breast cancer: A meta-analysis.".Medicine 98..5(2019):e14094
